| Name | Title | Contact Details |
|---|
Saint Luke's Hospital of Kansas City is a 582-bed tertiary care hospital offering many specialized programs and services, with a network of 550 physicians practicing in more than 56 medical specialties.
Endo Optiks Inc is a Little Silver, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Austin, we started as a single store with a mission to deliver outstanding results for our customers by providing supplements with the best-in-class ingredients and putting the customer`s experience first. Now more than 10 years later, we have evolved into Defyned Brands, a product development, brand marketing, and multi-channel retail company, owning 5 lifestyle supplement brands and over 50 retail stores under the name 5 Star Nutrition. We are passionate about putting our customers first by helping them reach their health and wellness potential.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Kronus is a Boise, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.